Table 5.
Supplementation with calcium and vitamin D (combined)
| Co-treatment | Year | N (%) | NTotal |
|---|---|---|---|
| Any treatment | 1st | 739 (61.3%) | 1206 |
| 2nd | 465 (63.6%) | 731 | |
| 3rd | 362 (69.1%) | 524 | |
| 4th | 300 (74.4%) | 403 | |
| Denosumab | 1st | 180 (70.0%) | 257 |
| 2nd | 163 (70.0%) | 233 | |
| 3rd | 150 (70.4%) | 213 | |
| 4th | 133 (74.7%) | 178 | |
| iv BP | 1st | 45 (60.0%) | 75 |
| 2nd | 19 (37.3%) | 51 | |
| 3rd | 13 (41.9%) | 31 | |
| 4th | 8 (47.1%) | 17 | |
| oral BP | 1st | 468 (57.6%) | 813 |
| 2nd | 270 (61.8%) | 437 | |
| 3rd | 191 (70.0%) | 273 | |
| 4th | 150 (76.1%) | 197 | |
| SR | 1st | 56 (69.1%) | 81 |
| 2nd | 18 (72.0%) | 25 | |
| 3rd | 11 (73.3%) | 15 | |
| 4th | 11 (73.3%) | 15 |